American Journal of Cardiology
Volume 105, Issue 1 , Pages 10-16 , 1 January 2010

Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years After Infarct-Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT])

  • Mariusz Kruk, MD

      Affiliations

    • Institute of Cardiology, Warsaw, Poland
    • ,
  • Christopher E. Buller, MD

      Affiliations

    • Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • James Enlou Tcheng, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University, Durham, North Carolina
    • ,
  • Vladimir Dzavík, MD

      Affiliations

    • Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada
    • ,
  • Venugopal Menon, MD

      Affiliations

    • Cleveland Clinic, Cleveland, Ohio
    • ,
  • G.B. John Mancini, MD

      Affiliations

    • Vancouver General Hospital, Vancouver, British Columbia, Canada
    • ,
  • Sandra A. Forman, MA

      Affiliations

    • Maryland Medical Research Institute, Baltimore, Maryland
    • ,
  • Peter Kurray, MD

      Affiliations

    • Middle Slovak Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia
    • ,
  • Benita Busz-Papiez, MD

      Affiliations

    • SP Wojewodzki Szpital Zespolony w Szczecinie, Szezecin, Poland
    • ,
  • Gervasio A. Lamas, MD

      Affiliations

    • Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami, Florida
    • ,
  • Judith S. Hochman, MD

      Affiliations

    • New York University School of Medicine, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: (212) 263-6927; fax: 212-263-7129

Received 15 June 2009 ,Revised 4 August 2009 ,Accepted 4 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by grants U01 HL062509 and U01 HL062511 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland. Supplemental grant funds and product donations equivalent to 6% of the total study cost were provided by Eli Lilly (Indianapolis, Indiana), Millennium Pharmaceuticals (Cambridge, Massachusetts) and Schering Plough (Kenilworth, New Jersey), Guidant (Indianapolis, Indiana), Cordis/Johnson & Johnson (Bridgewater, New Jersey), Medtronic (Minneapolis, Minnesota), Merck (Whitehouse Station, New Jersey), and Bristol Myers Squibb Medical Imaging (New York, New York).

 The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

 Dr. Hochman received grant support to her institution from Eli Lilly (Indianapolis, Indiana) and Bristol Myers Squibb Medical Imaging (New York, New York) and product donation from Millennium Pharmaceuticals (Cambridge, Massachusetts), Schering Plough (Kenilworth, New Jersey), Guidant (Indianapolis, Indiana), and Merck (Whitehouse Station, NJ) for OAT and received consultation fees from Bristol Myers Squibb (New York, New York), honoraria for Steering Committee service from CV Therapeutics (Palo Alto, California), Eli Lilly (Indianapolis, Indiana), and GlaxoSmithKline (Brentford, London, United Kingdom), and honoraria for serving on the Data Safety Monitoring Board of a trial supported by Schering Plough (Kenilworth, New Jersey). Dr. Mancini received a research grant from Cordis (Bridgewater, New Jersey) and honoraria of <$10,000/yr from Pfizer (New York, New York), Merck Frosst Canada (Kirkland, Quebec, Canada), AstraZeneca (London, United Kingdom), GSK (Brentford, London, United Kingdom), and Sanofi Aventis (Paris, France). Dr. Dzavík reports research, honorarium, and Advisory Board member funds from Cordis, Johnson & Johnson (Bridgewater, New Jersey), and honoraria from Boston Scientific (Natick, Massachusetts).

PII: S0002-9149(09)02209-7

doi: 10.1016/j.amjcard.2009.08.644

American Journal of Cardiology
Volume 105, Issue 1 , Pages 10-16 , 1 January 2010

Article Tools

* Image Usage & Resolution